In a clinical trial to evaluate IFN-γ as a prophylactic therapy for opportunistic infections in HIV+ patients, none receiving IFN-γ developed PML while 10% of those in the placebo group did (79). This evidence concerns the gene IFNG and Opportunistic infection.